

First-in-human study of the safety, pharmacokinetics, and efficacy of a first-in-class fatty acid synthase inhibitor TVB-2640 alone and in combination with pembrolizumab in patients with solid tumors

EClinicalMedicine

34, 100797

DOI: [10.1016/j.eclinm.2021.100797](https://doi.org/10.1016/j.eclinm.2021.100797)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. <i>Cells</i> , 2021, 10, 1056.	4.1	197
2	Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?. <i>Cancer Research</i> , 2021, 81, 4385-4393.	0.9	30
5	Prostate Cancer Progression: as a Matter of Fats. <i>Frontiers in Oncology</i> , 2021, 11, 719865.	2.8	27
6	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	1.3	101
7	Fibrometabolism—An emerging therapeutic frontier in pulmonary fibrosis. <i>Science Signaling</i> , 2021, 14, .	3.6	31
8	More Than Meets the Eye Regarding Cancer Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9507.	4.1	11
9	Nuclear Receptor-Mediated Metabolic Reprogramming and the Impact on HR+ Breast Cancer. <i>Cancers</i> , 2021, 13, 4808.	3.7	5
10	Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 558-580.	12.0	181
11	Review on target domains and natural compound-based inhibitors of fatty acid synthase for anticancer drug discovery. <i>Chemical Biology and Drug Design</i> , 2021, 98, 869-884.	3.2	9
13	Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. <i>Cell Death and Disease</i> , 2021, 12, 977.	6.3	33
14	Lipid metabolism in metastasis and therapy. <i>Current Opinion in Systems Biology</i> , 2021, 28, 100401.	2.6	10
15	Unravelling the Anticancer Mechanisms of Traditional Herbal Medicines with Metabolomics. <i>Molecules</i> , 2021, 26, 6541.	3.8	13
16	Lipid metabolism reprogramming in renal cell carcinoma. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 17-31.	5.9	37
17	The Epithelial—Mesenchymal Transition at the Crossroads between Metabolism and Tumor Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 800.	4.1	59
18	Lipogenesis inhibitors: therapeutic opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 283-305.	46.4	124
19	Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain. <i>Advances in Cancer Research</i> , 2022, 153, 267-304.	5.0	2
20	Therapeutic efficacy of FASN inhibition in preclinical models of HCC. <i>Hepatology</i> , 2022, 76, 951-966.	7.3	25
21	Clinical development of metabolic inhibitors for oncology. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	59

#	ARTICLE	IF	CITATIONS
22	Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?. <i>Frontiers in Oncology</i> , 2021, 11, 778761.	2.8	8
23	The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures. <i>Frontiers in Oncology</i> , 2021, 11, 792385.	2.8	1
24	Defining the landscape of metabolic dysregulations in cancer metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 345-362.	3.3	8
25	Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1624-1635.	12.0	12
26	Cancer Stem Cells in Ovarian Cancer—A Source of Tumor Success and a Challenging Target for Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2496.	4.1	24
27	Synthesis and Evaluation of ¹¹ C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography. <i>Molecules</i> , 2022, 27, 1552.	3.8	0
28	Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer. <i>Nutrients</i> , 2022, 14, 851.	4.1	17
29	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 6231.	3.7	13
31	Fatty acid synthase as a potential new therapeutic target for cervical cancer. <i>Anais Da Academia Brasileira De Ciencias</i> , 2022, 94, e20210670.	0.8	4
32	Fatty acid synthase: a druggable driver of breast cancer brain metastasis. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 427-444.	3.4	10
33	The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer. <i>Trends in Cancer</i> , 2022, 8, 556-569.	7.4	13
35	Tissue-Specific Downregulation of Fatty Acid Synthase Suppresses Intestinal Adenoma Formation via Coordinated Reprogramming of Transcriptome and Metabolism in the Mouse Model of Apc-Driven Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6510.	4.1	9
36	Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy. <i>Current Protein and Peptide Science</i> , 2022, 23, 585-601.	1.4	1
37	Genomic Characteristics, Metabolic Signature and Immune Microenvironment of <i>Clonorchis Sinensis</i> -Related Intrahepatic Cholangiocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
38	MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. <i>Nature Communications</i> , 2022, 13, .	12.8	18
39	Tumor metabolic reprogramming in lung cancer progression (Review). <i>Oncology Letters</i> , 2022, 24, .	1.8	13
40	The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
41	Emerging roles of fatty acid metabolism in cancer and their targeted drug development. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114613.	5.5	4

#	ARTICLE	IF	CITATIONS
42	Lipid Metabolism in Glioblastoma: From De Novo Synthesis to Storage. <i>Biomedicines</i> , 2022, 10, 1943.	3.2	19
43	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9391.	4.1	13
44	The vacuole shapes the nucleus and the ribosomal DNA loop during mitotic delays. <i>Life Science Alliance</i> , 2022, 5, e202101161.	2.8	2
45	FASN inhibitor TVB-3166 prevents S-acylation of the spike protein of human coronaviruses. <i>Journal of Lipid Research</i> , 2022, 63, 100256.	4.2	5
46	TGF- β 2 signaling in the tumor metabolic microenvironment and targeted therapies. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	35
47	Lipid metabolism in pancreatic cancer: emerging roles and potential targets. <i>Cancer Communications</i> , 2022, 42, 1234-1256.	9.2	21
48	Interplay between fat cells and immune cells in bone: Impact on malignant progression and therapeutic response. , 2022, 238, 108274.		0
49	Energy metabolism pathways in breast cancer progression: The reprogramming, crosstalk, and potential therapeutic targets. <i>Translational Oncology</i> , 2022, 26, 101534.	3.7	5
50	The role of fatty acids metabolism on cancer progression and therapeutics development. , 2023, , 101-132.		0
51	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	35
53	FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. <i>Scientific Reports</i> , 2022, 12, .	3.3	17
54	A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth. <i>Blood</i> , 0, , .	1.4	7
55	Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets. <i>Nature Reviews Urology</i> , 2023, 20, 48-60.	3.8	24
56	Revisiting potential value of antitumor drugs in the treatment of COVID-19. <i>Cell and Bioscience</i> , 2022, 12, .	4.8	1
57	Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. <i>Biomolecules</i> , 2022, 12, 1590.	4.0	6
58	The role of lipids in cancer progression and metastasis. <i>Cell Metabolism</i> , 2022, 34, 1675-1699.	16.2	82
59	Acetyl-CoA: An interplay between metabolism and epigenetics in cancer. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	1.9	1
60	Progress of potential drugs targeted in lipid metabolism research. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	5

#	ARTICLE	IF	CITATIONS
61	Overview of Cancer Metabolism and Signaling Transduction. International Journal of Molecular Sciences, 2023, 24, 12.	4.1	9
62	Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer. Technology in Cancer Research and Treatment, 2022, 21, 153303382211406.	1.9	4
63	Fatty Acid Synthase (FASN): A Patent Review Since 2016-Present. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, .	1.6	1
64	Proteomic markers in breast cancer diagnosis and treatment. Makedonsko Farmaceutski Bilten, 2022, 68, 355-356.	0.0	0
65	Targeting lipid metabolism in metastatic prostate cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311528.	3.2	5
66	The role of cancer cell bioenergetics in dormancy and drug resistance. Cancer and Metastasis Reviews, 2023, 42, 87-98.	5.9	6
67	Recent updates on targeting the molecular mediators of NAFLD. Journal of Molecular Medicine, 2023, 101, 101-124.	3.9	3
68	Metabolic reprogramming in colorectal cancer: regulatory networks and therapy. Cell and Bioscience, 2023, 13, .	4.8	9
69	Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials. EclinicalMedicine, 2023, 57, 101827.	7.1	0
70	ncRNA-mediated fatty acid metabolism reprogramming in HCC. Trends in Endocrinology and Metabolism, 2023, 34, 278-291.	7.1	8
72	Metabolomics in oncology. Cancer Reports, 2023, 6, .	1.4	3
73	Fatty acids in cancer: Metabolic functions and potential treatment. , 2023, 2, .		2
74	Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. Cancers, 2023, 15, 1936.	3.7	6
75	Prostate Cancer: Advances in Genetic Testing and Clinical Implications. Uro, 2023, 3, 91-103.	0.8	1
76	Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies. Oncogenesis, 2023, 12, .	4.9	9
77	PHF6 recruits BPTF to promote HIF-dependent pathway and progression in YAP-high breast cancer. Journal of Translational Medicine, 2023, 21, .	4.4	0
78	Fatty acid metabolism: A new therapeutic target for cervical cancer. Frontiers in Oncology, 0, 13, .	2.8	2
79	The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications. Molecular Diagnosis and Therapy, 0, , .	3.8	2

#	ARTICLE	IF	CITATIONS
80	Metabolic dependencies and targets in ovarian cancer. , 2023, 245, 108413.		8
81	Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	8.6	1
82	Obesity-induced changes in cancer cells and their microenvironment: Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism. Seminars in Cancer Biology, 2023, 93, 36-51.	9.6	6
83	Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma. Clinical Cancer Research, 2023, 29, 2419-2425.	7.0	6
84	Physiological and pathological roles of lipogenesis. Nature Metabolism, 2023, 5, 735-759.	11.9	21
85	NFYA promotes malignant behavior of triple-negative breast cancer in mice through the regulation of lipid metabolism. Communications Biology, 2023, 6, .	4.4	3
86	Metabolic reprogramming of clear cell renal cell carcinoma. Frontiers in Endocrinology, 0, 14, .	3.5	1
87	The Interplay between Dysregulated Metabolism and Epigenetics in Cancer. Biomolecules, 2023, 13, 944.	4.0	1
88	Atomic model for core modifying region of human fatty acid synthase in complex with Denifanstat. Nature Communications, 2023, 14, .	12.8	4
89	An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets. Cancer Cell, 2023, 41, 1327-1344.e10.	16.8	5
90	Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities. Current Breast Cancer Reports, 0, , .	1.0	0
91	<sc>BCKDHA</sc> contributes to melanoma progression by promoting the expressions of lipogenic enzymes <sc>FASN</sc> and <sc>ACLY</sc>. Experimental Dermatology, 0, , .	2.9	1
92	Lipid metabolism in the immune niche of tumor-prone liver microenvironment. Journal of Leukocyte Biology, 2024, 115, 68-84.	3.3	2
93	FAM120A couples SREBP-dependent transcription and splicing of lipogenesis enzymes downstream of mTORC1. Molecular Cell, 2023, 83, 3010-3026.e8.	9.7	2
94	Fatty acids in cancer chemoresistance. Cancer Letters, 2023, 572, 216352.	7.2	1
95	Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. Journal of Hematology and Oncology, 2023, 16, .	17.0	11
96	Tumor microenvironmental nutrients, cellular responses, and cancer. Cell Chemical Biology, 2023, 30, 1015-1032.	5.2	2
97	Targeting fatty acid uptake and metabolism in cancer cells: A promising strategy for cancer treatment. Biomedicine and Pharmacotherapy, 2023, 167, 115591.	5.6	1

#	ARTICLE	IF	CITATIONS
98	BCAT2 promotes melanoma progression by activating lipogenesis via the epigenetic regulation of FASN and ACLY expressions. Cellular and Molecular Life Sciences, 2023, 80, .	5.4	0
99	Acetyl-CoA metabolism as a therapeutic target for cancer. Biomedicine and Pharmacotherapy, 2023, 168, 115741.	5.6	2
100	Metabolic pathway analysis using stable isotopes in patients with cancer. Nature Reviews Cancer, 2023, 23, 863-878.	28.4	6
101	Computational study on natural molecules targeting $\hat{1}^2$ -ketoacyl reductase domain of fatty acid synthase for the identification of selective inhibitors. Journal of Biomolecular Structure and Dynamics, 0, , 1-22.	3.5	0
102	Targeting dysregulated lipid metabolism in the tumor microenvironment. Archives of Pharmacal Research, 0, , .	6.3	0
103	Fatty Acid Synthase Inhibitors Enhance Microtubule-Stabilizing and Microtubule-Destabilizing Drugs in Taxane-Resistant Prostate Cancer Cells. ACS Pharmacology and Translational Science, 2023, 6, 1859-1869.	4.9	0
104	The lipid metabolism remodeling: A hurdle in breast cancer therapy. Cancer Letters, 2024, 582, 216512.	7.2	1
105	Mitochondrial metabolism as a dynamic regulatory hub to malignant transformation and anti-cancer drug resistance. Biochemical and Biophysical Research Communications, 2024, 694, 149382.	2.1	0
106	Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. Cancer Research, 2024, 84, 703-724.	0.9	0
107	Targeting lipid metabolism in cancer metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2024, 1879, 189051.	7.4	0
108	FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-Genomic Features of Prostate Cancer. Cancer Research Communications, 0, , .	1.7	0
109	Metabolomics at the tumor microenvironment interface: Decoding cellular conversations. Medicinal Research Reviews, 2024, 44, 1121-1146.	10.5	0
110	The Fatty Acid Synthase (FASN) signalome: A molecular guide for precision oncology. Molecular Oncology, 0, , .	4.6	0
111	The lipid droplet in cancer: From being a tumorâ€supporting hallmark to clinical therapy. Acta Physiologica, 2024, 240, .	3.8	0
112	Real-Time NMR-Based Drug Discovery to Identify Inhibitors against Fatty Acid Synthesis in Living Cancer Cells. Analytical Chemistry, 0, , .	6.5	0
113	Metabolic basis of cardiac dysfunction in cancer patients. Current Opinion in Cardiology, 2024, 39, 138-147.	1.8	0
114	Lipid droplets provide metabolic flexibility for cancer progression. FEBS Letters, 0, , .	2.8	0
115	Altered lipid metabolism in APC-driven colorectal cancer: the potential for therapeutic intervention. Frontiers in Oncology, 0, 14, .	2.8	0